Standout Papers

Liraglutide and Cardiovascul... 1993 2026 2004 2015 4.7k
  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016)
    Steven P. Marso, Gilbert H. Daniels et al. New England Journal of Medicine
  2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2006)
    Daniel J. Drucker, Michael A. Nauck The Lancet
  3. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  4. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  5. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. (1993)
    Michael A. Nauck, Markus M. Heimesaat et al. Journal of Clinical Investigation
  6. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes (1986)
    Michael A. Nauck, F. Stöckmann et al. Diabetologia
  7. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes (2008)
    Michael A. Nauck, Anders Frid et al. Diabetes Care
  8. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients (1993)
    Michael A. Nauck, N. Kleine et al. Diabetologia
  9. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020)
    Michael A. Nauck, Daniel R. Quast et al. Molecular Metabolism
  10. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans (1997)
    Michael A. Nauck, Jens J. Holst et al. American Journal of Physiology-Endocrinology and Metabolism
  11. Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses* (1986)
    Michael A. Nauck, E. G. Siegel et al. The Journal of Clinical Endocrinology & Metabolism
  12. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects (1995)
    Carolyn F. Deacon, Michael A. Nauck et al. Diabetes
  13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (2018)
    Juan P. Frías, Michael A. Nauck et al. The Lancet
  14. COVID-19 and diabetes mellitus: from pathophysiology to clinical management (2020)
    Soo Lim, Jae Hyun Bae et al. Nature Reviews Endocrinology
  15. Incretin hormones: Their role in health and disease (2018)
    Michael A. Nauck, Juris J. Meier Diabetes Obesity and Metabolism
  16. Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects (1995)
    Carolyn F. Deacon, Michael A. Nauck et al. Diabetes
  17. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetologia
  18. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial (2007)
    Michael A. Nauck, Gary Meininger et al. Diabetes Obesity and Metabolism
  19. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial (2010)
    Richard E. Pratley, Michael A. Nauck et al. The Lancet
  20. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (2012)
    John B. Buse, Michael A. Nauck et al. The Lancet
  21. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin (2011)
    Michael A. Nauck, Stefano Del Prato et al. Diabetes Care
  22. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors (2017)
    Michael A. Nauck, Juris J. Meier et al. Circulation
  23. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial (2019)
    Richard E. Pratley, Aslam Amod et al. The Lancet
  24. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions (2016)
    Michael A. Nauck, Juris J. Meier The Lancet Diabetes & Endocrinology
  25. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes (2021)
    Matthew C. Riddle, William T. Cefalu et al. Diabetes Care
  26. The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update (2021)
    Michael A. Nauck, Daniel R. Quast et al. Diabetes Obesity and Metabolism
  27. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction (2022)
    Michael A. Nauck et al. Cardiovascular Diabetology
  28. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes (2021)
    Michael A. Nauck, Jakob Wefers et al. The Lancet Diabetes & Endocrinology
  29. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  30. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal

Immediate Impact

3 by Nobel laureates 4 from Science/Nature 229 standout
Sub-graph 1 of 13

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
116 intermediate papers

Works of Michael A. Nauck being referenced

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
2023 Standout
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
2018 Standout
and 90 more

Author Peers

Author Last Decade Papers Cites
Michael A. Nauck 37927 16924 17440 374 45.6k
Julio Rosenstock 28472 11084 11208 407 34.5k
Bernard Zinman 43046 18193 17578 643 61.2k
Sten Madsbad 16568 6987 11452 537 26.7k
Steven E. Kahn 20367 12423 12627 467 45.2k
Ralph A. DeFronzo 23648 20450 11716 411 50.5k
Ele Ferrannini 28308 14917 13056 523 50.0k
Markku Laakso 22794 15999 11434 667 56.6k
Tina Vilsbøll 14339 6742 7870 447 19.5k
Richard E. Pratley 16147 8472 6320 392 34.6k
Jean‐Charles Fruchart 7114 15619 10128 380 31.3k

All Works

Loading papers...

Rankless by CCL
2026